STOCK TITAN

Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS), a company dedicated to precision oncology, will participate in the Bank of America Securities Precision Oncology Conference on October 3, 2022, at 3:40 PM ET. CEO Jonathan E. Lim and CFO David M. Chacko will engage in a virtual fireside chat and one-on-one investor meetings. A live webcast will be available, with an archived replay until January 3, 2023. Erasca aims to innovate therapies for RAS/MAPK pathway-driven cancers, leveraging a strong pipeline and expert advisory board to achieve its mission of erasing cancer.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities Precision Oncology Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat at 3:40 pm Eastern Time on Monday, October 3, 2022. Drs. Lim and Chacko will also participate in one-on-one investor meetings.

A live webcast of the event will be available online at https://bofa.veracast.com. An archived replay of the event will be available until January 3, 2023, following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.


FAQ

What is the date and time of Erasca's presentation at the Bank of America Securities Conference?

Erasca will present on October 3, 2022, at 3:40 PM ET.

Who will represent Erasca during the virtual fireside chat?

CEO Jonathan E. Lim and CFO David M. Chacko will represent Erasca.

Where can I watch the Erasca presentation from the conference?

The presentation will be available via a live webcast at the Bank of America Securities website.

When will the archived replay of the Erasca event be available until?

The archived replay will be available until January 3, 2023.

What is the focus of Erasca as a company?

Erasca focuses on discovering and developing therapies for RAS/MAPK pathway-driven cancers.

Erasca, Inc.

NASDAQ:ERAS

ERAS Rankings

ERAS Latest News

ERAS Stock Data

795.25M
282.50M
12.4%
77.06%
11.93%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO